Evofem Biosciences, Inc. (EVFM) financial statements (2021 and earlier)

Company profile

Business Address 12400 HIGH BLUFF DRIVE
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:498712410163251
Cash and cash equivalents49871249163251
Other undisclosed cash, cash equivalents, and short-term investments 002   
Restricted cash and investments23000000
Receivables11     
Inventory, net of allowances, customer advances and progress billings731    
Inventory731    
Other undisclosed current assets1811331152
Total current assets:9810212814263853
Noncurrent Assets
Operating lease, right-of-use asset7750   
Property, plant and equipment4211010
Other noncurrent assets1111111
Other undisclosed noncurrent assets    000
Total noncurrent assets:121072212
TOTAL ASSETS:11011213516283954
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities22151714121518
Accounts payable11587659
Accrued liabilities4532367
Employee-related liabilities7565432
Debt524844    
Other liabilities11     
Other undisclosed current liabilities2210001
Total current liabilities:77666214131519
Noncurrent Liabilities
Long-term debt and lease obligation31650   
Long-term debt, excluding current maturities25      
Operating lease, liability6650   
Other undisclosed noncurrent liabilities(6)(6)(5)(0)   
Total noncurrent liabilities:25650   
Total liabilities:109726715131519
Stockholders' equity
Stockholders' equity attributable to parent140691162436
Common stock0000000
Additional paid in capital657655654533529525522
Accumulated deficit(655)(615)(585)(532)(513)(500)(487)
Total stockholders' equity:140691162436
TOTAL LIABILITIES AND EQUITY:11011213516283954

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues00     
Cost of revenue
(Cost of Goods and Services Sold)
(0)(0)     
Gross profit:0(0)     
Operating expenses68(26)(22)(19)(13)(14)(12)
Other undisclosed operating income (loss)(104)0     
Operating loss:(36)(26)(22)(19)(13)(14)(12)
Nonoperating income (expense)(5)(4)(30)000(24)
Investment income, nonoperating0000000
Other nonoperating income (expense)(1)(1)(0)(0)00(0)
Interest and debt expense(1)      
Other undisclosed income from continuing operations before equity method investments, income taxes2      
Loss from continuing operations before equity method investments, income taxes:(40)(30)(53)(19)(13)(14)(35)
Other undisclosed loss from continuing operations before income taxes(1)      
Loss from continuing operations before income taxes:(41)(30)(53)(19)(13)(14)(35)
Income tax expense(0)(0)    (0)
Net loss available to common stockholders, diluted:(41)(30)(53)(19)(13)(14)(35)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(41)(30)(53)(19)(13)(14)(35)
Comprehensive loss, net of tax, attributable to parent:(41)(30)(53)(19)(13)(14)(35)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: